Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART-ddBCMA |
Synonyms | |
Therapy Description |
CART-ddBCMA are autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) with a synthetic antigen-binding domain targeting BCMA (TNFRSF17) and containing CD137 (4-1BB) and CD3 zeta signaling domains, which potentially have antitumor activity (PMID: 35468618). |